I think that is exactly the model that Mr. Ehrlich has in mind. He's used the term "royalty company" in, I think, a conference call, if not a written document.

If we got a modest 500 million up front for one of the drugs, the company could easily afford a $3-4 special dividend, and still fund further research on the other drugs. I'd love to see that